Our product delivers pharmaceuticals – vaccines and drugs - through the skin. We accomplish this using jet injection technology. We do not use needles – big or small, or patches of any kind.
Our needle-free delivery device is FDA cleared for marketing. It can deliver 0.5 ml of a liquid medication through the skin of the arm, the abdomen or the thigh, into the muscle (intramuscular or IM area) where many vaccines are routinely delivered, or into the subcutaneous layer or SC depth between the skin and muscle, where other drugs are injected. In fact, the PharmaJet needle-free delivery device can be used to inject just about any licensed injectable liquid medicine.
We have a pipeline of new products underway. A 0.1 ml device is under development for intradermal delivery into the 2 mm upper layer of the skin where the immune system is very active.
Our mission to serve the global community is shared by employees and investors. We want fewer needle injections because it means a safer work place with less exposure to needle stick injuries, reduces the amount of hazardous sharps medical waste and provides better control over the spread of blood borne HIV and hepatitis from needle reuse.
We would like to help children avoid needle jabs when bravely taking their childhood vaccinations and booster shots. We also serve their pediatricians, and nurses who give the shots, and tens of millions of "belenophobics" who until now have had no practical recourse to their fear of needles.
We are a maturing medical device company with a better jet injector. Our opportunity to serve individual patients and also public health needs worldwide is enormous. If you share our mission and are interested in working here, collaborating with us, or purchasing our device, then please contact us. We are located in Denver, Colorado, San Francisco, California and Baltimore, Maryland.
James Bowman, President and Chief Operating Officer, has a bachelor of science degree in biomedical engineering from Marquette University and is an alumnus of Harvard Business School. Jim's career in medical devices spans more than 25 years focused on the commercialization of innovative early-stage technologies. He has held senior leadership positions in growing life science companies including CEO of public and private companies. Jim has driven business development of disruptive technologies in companies such as, C.R. BARD, OHMEDA, Encision, CytoLogic, Tissue Genetics and Surgical Laser Technologies.
Linda McAllister, MD. Ph.D., Vice President R&D and Chief Medical Officer. Formerly Assistant Clinical Professor of Medicine at UCSF and Attending Physician in the SFGH ER and UCSF. Dr. McAllister has worked at Affymetrix, Celera and at Roche, where she was Director of Technology Management. Most recently at Arbor Vita she was EVP & CMO, where she managed the FDA approval of devices for detecting influenza and cervical cancer/HPV. Her B.S. is from Caltech; M.D. from Stanford, and Ph.D. from Stanford University.
Michael Royals, DVM, Global Head of Applications Development. Brings 15 years of medical device design and commercialization experience to the company and manages the company's global research and technology application collaborations. DVM from Colorado State University.
Philip Vorwald, Chief Commercial Officer. Former Vice-President of Becton Dickinson Biosciences Europe with over 25 years of experience in sales, marketing and business development, and general management in biotech start ups. Manages all commercial aspects of product sales, marketing and customer support. BS from Catholic University and MS from Medical College of Virginia.
Maureen Cullum, Vice President & Chief Financial Officer. Ms. Cullum brings over 25 years of practical experience in various accounting, finance and operational roles, including 13 years in executive officer positions within start-up companies operating internationally, involving private equity and foreign multinational investors, including NYNEX, HBO, Sony and Disney. Maureen holds a B.S. from Boston College in accounting, and an MBA from Bentley College.
Gary Ashurst, VP, Manufacturing. Mr. Ashurst joined PharmaJet from Baxa Corporation, where he held a variety of roles in manufacturing and operations management, including Baxa's director of operations, director of process engineering and most recently as director of operations project management. He has also worked with contract manufacturing organizations in Europe and Mexico. Gary has a BS in engineering from Colorado State University, and masters degree in Technology Management from The University of Denver.
Ron Bauer, Executive Director of Quality and Regulatory Affairs. 25 years of engineering, Quality Systems, and Regulatory Affairs management, at MedSource, Honeywell and Aspen Laboratories. Manages PharmaJet's regulatory clearances, and ISO compliance. BS in engineering from Metropolitan State College.
John Bingham, Design and Production Engineering Chief. 20 years of experience in industrial design, mold design, product development, rapid prototyping and manufacturing, owned and managed two injection molding companies. Holds several patents.
Tony Allard, Director, is President of Hearthstone Investments, which focuses on investing in Western Canada. He has practiced securities law in British Columbia and he holds a B.A. and L.L.B. from the University of Alberta.
Ann Arvin M.D. is the Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology & Immunology, Stanford University School of Medicine. Her research laboratory investigates the varicella-zoster virus (VZV, chicken pox); her clinical research examines immunity in infants and young children in response to viral infections and vaccines, including influenza vaccines. She is a member of the Institute of Medicine and serves on the Board on Life Sciences of the NAS/NRC, the director’s Advisory Council of the NIH NIAID, and was a member of the Planning Group on Pandemic Influenza Research Gaps, IOM, 2005, the NIAID Blue Ribbon Panel on Influenza, 2006, and the working group on novel H1N1 of the President's Advisory Council on Science & Technology, 2009.
Spike Buckley, Director. Mr. Buckley has a background as a commercial real estate developer, with investments spanning from West to East coasts in the US, and Canada, from his Colorado office. He is an active angel investor in high- tech and bio-tech companies in Canada and the U.S., which includes medical devices and tools that aid in drug delivery and diagnostic activities. He is an active board participant, locally, in the Corridor Business Improvement District and Colorado Veterinary Medical Foundation. He holds a BA in Economics from the University of Colorado.
Kathy Callender, Founder. 35 years of experience in clinical health care, patient care and international medical social work. She teaches and trains nurses and health care workers and champions our mission around the world. BS from University of Missouri.
Cornelia Dekker, M.D. Dr. Dekker is a Professor (Research) of Pediatrics – Infectious Diseases at Stanford University and serves as the current Medical Director of the Stanford-LPCH Vaccine Program. She is also a Member of the HIV Vaccine Trial Network Safety Monitoring Board as well as a Member of the Stanford GCRC Advisory Committee. Her clinical focus is on pediatric infectious disease and vaccine clinical trials. She holds an MD degree from Michigan State and residency and fellowship work at Duke University Medical Center.
Kim Duncan, Director, is Principal of Kulik Investments, a private investment fund focused on early stage venture and private equity investments. Formerly Mr. Duncan was with Goldman Sachs and he holds a B.S. from Yale University.
Ronald Lowy, Co-Chairman. Ron Lowy is the current President and CEO of the RAL Group, an independent consulting firm focused on business development strategy and execution. His group serves clients in the healthcare, drug discovery and medical device businesses. Mr. Lowy was previously President and CEO of Fisher Biosciences and worked closely with Thermo Electron Corporation during their merger to create ThermoFisher Scientific. He previously held senior management positions at ADC Telecommunications and GE Medical Systems. Mr. Lowy holds an MBA from the University of Wisconsin and a BS in Mechanical Engineering from the University of New Hampshire.
Laurence Marton M.D. Formerly Dean of the University of Wisconsin-Madison Medical School and Chair of the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. He is Chief Scientific Officer of Progen Pharmaceuticals and previously held similar positions at Cellgate and SLIL Biomedical. He serves as a consultant for industry and for governmental and academic institutions and was appointed by the Governor of Wisconsin to the Wisconsin Technology Council.
Paul Mendelman, M.D. Dr. Mendelman is Executive Vice President and Chief Medical Officer at Ligocyte Pharmaceuticals, Inc. He was the former Vice President for clinical development, infectious diseases and vaccines at Aviron, Inc. from 1996 to 2002 and was promoted to therapeutic group leader in 2003 after the acquisition of Aviron by MedImmune, Inc. Dr. Mendelman was a senior research physician in infectious diseases and vaccines for Merck Research Laboratories from 1991 to 1996. He received his BS and MD degrees from Ohio State University.
Joel Palefsky M.D. Professor of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections. He is Director of the world's first clinic devoted to prevention of anal cancer, at UCSF. He is the chair of the HPV Working Group of the AIDS Malignancy Consortium and is co-director of the Cancer and Immunology Program of the UCSF Comprehensive Cancer Center.
Markus Pedriks, Director. Operational leadership and entrepreneur in Europe and North America in health, media, telecommunications, entertainment and real estate. MBA from IMD, Lausanne and BA in Economics from McGill University, Montreal.
Heather Potters, Chairman. Investor. Nearly 20 years in Private Equity fund management and international investment. (BCEE; Enterprise Investors); hands-on role in international business development and fund raising. MBA from Wharton and B.A. in International Management from Claremont McKenna College.
